CN103435598B - 巴拉塞替的制备方法 - Google Patents
巴拉塞替的制备方法 Download PDFInfo
- Publication number
- CN103435598B CN103435598B CN201310316119.5A CN201310316119A CN103435598B CN 103435598 B CN103435598 B CN 103435598B CN 201310316119 A CN201310316119 A CN 201310316119A CN 103435598 B CN103435598 B CN 103435598B
- Authority
- CN
- China
- Prior art keywords
- lasai
- preparation
- amino
- condensation reaction
- replaces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000006482 condensation reaction Methods 0.000 claims abstract description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 15
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims abstract description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 239000002585 base Substances 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- -1 (dimethylamino) phosphorus hexafluorophosphate Chemical compound 0.000 claims description 6
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 3
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 239000012964 benzotriazole Substances 0.000 claims description 2
- 229940043232 butyl acetate Drugs 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- 229940093499 ethyl acetate Drugs 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- GBJVVSCPOBPEIT-UHFFFAOYSA-N AZT-1152 Chemical compound N=1C=NC2=CC(OCCCN(CC)CCOP(O)(O)=O)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 GBJVVSCPOBPEIT-UHFFFAOYSA-N 0.000 abstract description 7
- 229950005645 barasertib Drugs 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000005457 optimization Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 150000007530 organic bases Chemical class 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 5
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000004821 distillation Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical group NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000003989 Aurora kinases Human genes 0.000 description 1
- 108090000433 Aurora kinases Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 C*1C(CCC2c(ccc(OCCC*(CC*)IC)c3)c3*=C*2C)=CC(CC(*c2cccc(N)c2)=O)=*1 Chemical compound C*1C(CCC2c(ccc(OCCC*(CC*)IC)c3)c3*=C*2C)=CC(CC(*c2cccc(N)c2)=O)=*1 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310316119.5A CN103435598B (zh) | 2013-07-25 | 2013-07-25 | 巴拉塞替的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310316119.5A CN103435598B (zh) | 2013-07-25 | 2013-07-25 | 巴拉塞替的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103435598A CN103435598A (zh) | 2013-12-11 |
CN103435598B true CN103435598B (zh) | 2015-08-05 |
Family
ID=49689336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310316119.5A Active CN103435598B (zh) | 2013-07-25 | 2013-07-25 | 巴拉塞替的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103435598B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101443339A (zh) * | 2006-05-16 | 2009-05-27 | 阿斯利康(瑞典)有限公司 | 制备包含磷酸酯基的吡唑基氨基喹唑啉衍生物的方法 |
CN101448501A (zh) * | 2006-05-16 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 用于癌治疗的组合疗法 |
CN102153519A (zh) * | 2011-02-18 | 2011-08-17 | 上海长林化学科技有限公司 | 一类喹唑啉衍生物的制备方法 |
-
2013
- 2013-07-25 CN CN201310316119.5A patent/CN103435598B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101443339A (zh) * | 2006-05-16 | 2009-05-27 | 阿斯利康(瑞典)有限公司 | 制备包含磷酸酯基的吡唑基氨基喹唑啉衍生物的方法 |
CN101448501A (zh) * | 2006-05-16 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 用于癌治疗的组合疗法 |
CN102153519A (zh) * | 2011-02-18 | 2011-08-17 | 上海长林化学科技有限公司 | 一类喹唑啉衍生物的制备方法 |
Non-Patent Citations (3)
Title |
---|
An Efficient Direct Amination of Cyclic Amides and Cyclic Ureas;Zhao-Kui Wan, et al;《ORGANIC LETTERS》;20060506;第8卷(第11期);2425-2428 * |
Discovery, Synthesis, and in ViWo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase;Andrew A. Mortlock, et al;《J. Med. Chem.》;20070321;第50卷(第9期);2213-2224 * |
The Scope and Mechanism of Phosphonium-Mediated SNAr Reactions in Heterocyclic Amides and Ureas;Zhao-Kui Wan, et al;《J. Org. Chem.》;20071129;第72卷(第26期);10194-10210 * |
Also Published As
Publication number | Publication date |
---|---|
CN103435598A (zh) | 2013-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103254179B (zh) | 阿伐那非的制备方法 | |
CN103265534B (zh) | 阿伐那非的制备方法 | |
CN103288808B (zh) | 一种阿法替尼的制备方法 | |
CN103254180B (zh) | 一种阿伐那非的制备方法 | |
CN103288758B (zh) | 一种达克米替尼的制备方法 | |
WO2013107428A1 (zh) | 7-位取代的汉防己乙素衍生物、及其制备方法和应用 | |
CN103242303A (zh) | 阿法替尼的制备方法 | |
Gu et al. | Novel Synthetic Route to α‐Aminophosphonates Containing Benzothiazole Moiety | |
CN103922992B (zh) | 一种抗癌活性吲哚酮衍生物、合成方法及其用途 | |
CN103288804A (zh) | 一种尼洛替尼的制备方法 | |
CN104311485A (zh) | 一种治疗白血病的药物博舒替尼的制备方法 | |
CN103275072B (zh) | 塞卡替尼的制备方法 | |
CN103435598B (zh) | 巴拉塞替的制备方法 | |
CN103304535B (zh) | 叠氮化合物及其制备方法 | |
CN108191849B (zh) | 一种抗表皮生长因子受体耐药性突变抑制剂的制备方法、相关中间体及应用 | |
CN103351386A (zh) | 一种盐酸阿扎司琼的合成方法 | |
CN104557877A (zh) | 一种阿伐那非中间体及其制备方法和应用 | |
CN103275069B (zh) | 西地尼布的制备方法 | |
CN103265497B (zh) | 一种替尼类抗肿瘤药合成所需中间体4-氯-6-氨基-7-羟基喹唑啉及其制备方法 | |
CN106046028A (zh) | 具有组蛋白去甲基化酶抑制活性天然产物的合成 | |
CN103242245B (zh) | 坦度替尼的制备方法 | |
CN104610247B (zh) | 一种半合成紫杉烷衍生物及其制备方法和应用 | |
CN108658981A (zh) | 一种6-溴-4-甲氧基氢-吡唑[1,5-a]吡啶-3-甲腈的合成方法 | |
CN113845523B (zh) | 多环喹啉衍生物及其制备和应用 | |
CN111592531B (zh) | 福瑞塞替的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200108 Address after: No. 2-3-2-1, Fuyuan apartment, Suizhou North Road, Suining economic and Technological Development Zone, Sichuan Province Patentee after: Sichuan Tiandi Renhe Technology Co., Ltd Address before: 215000 Jiangsu Province, Suzhou City Industrial Park Commercial Plaza Building 1 room 1305 Lianfeng Co-patentee before: Xu Xuenong Patentee before: Suzhou Mingyue Medical Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200417 Address after: No. 403, Zone G, No. 8, Beida South Road, xixiantang District, Nanning City, Guangxi Zhuang Autonomous Region, 530000 Patentee after: Guangxi Dingrui Technology Service Co., Ltd Address before: No. 2-3-2-1, Fuyuan apartment, Suizhou North Road, Suining economic and Technological Development Zone, Sichuan Province Patentee before: Sichuan Tiandi Renhe Technology Co., Ltd |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200803 Address after: 223800 north side of Xiangjiang Road, Sihong Economic Development Zone, Suqian City, Jiangsu Province Patentee after: Jiangsu Panlong Construction Co., Ltd Address before: No. 403, Zone G, No. 8, Beida South Road, xixiantang District, Nanning City, Guangxi Zhuang Autonomous Region, 530000 Patentee before: Guangxi Dingrui Technology Service Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200825 Address after: No.108 Yanhe Road, Luji street, Jiepai Town, Binhai County, Yancheng City, Jiangsu Province Patentee after: Jiangsu zhouyu Construction Co., Ltd Address before: 223800 north side of Xiangjiang Road, Sihong Economic Development Zone, Suqian City, Jiangsu Province Patentee before: Jiangsu Panlong Construction Co., Ltd |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201126 Address after: No.31 Renmin East Road, Chengdong Street office, Linquan County, Fuyang City, Anhui Province Patentee after: Linquan Lianzheng e-commerce Co., Ltd Address before: No.108 Yanhe Road, Luji street, Jiepai Town, Binhai County, Yancheng City, Jiangsu Province Patentee before: Jiangsu zhouyu Construction Co., Ltd |
|
TR01 | Transfer of patent right |